Breast Cancer Research and Treatment

, Volume 76, Issue 2, pp 137–143 | Cite as

Mega-Dose Vitamins and Minerals in the Treatment of Non-Metastatic Breast Cancer: An Historical Cohort Study

  • M.L. Lesperance
  • I.A. Olivotto
  • N. Forde
  • Y. Zhao
  • C. Speers
  • H. Foster
  • M. Tsao
  • N. MacPherson
  • A. Hoffer


Background. Alternative therapies such as mega-dose vitamins and minerals are commonly used by women with breast cancer, but their effect on recurrence and survival have rarely been evaluated.

Methods. Survival and recurrence outcomes for 90 women with unilateral non-metastatic breast cancer diagnosed between 1989 and 1998, and who had been prescribed mega-doses of beta-carotene, vitamin C, niacin, selenium, coenzyme Q10, and zinc in addition to standard therapies were compared with matched controls. The 90 treated patients were prescribed combinations from three to six of the vitamins and minerals listed above. The controls were matched (2:1) to the vitamin/mineral patients for age at diagnosis, presence of axillary lymph node metastasis, tumor stage, grade, estrogen receptor status, year of diagnosis, and prescription of systemic therapy. All subjects were patients of the British Columbia Cancer Agency, Vancouver Island Centre.

Findings. Median follow-up of surviving patients was 68 months (minimum 20 months, 133 months maximum). The vitamin/mineral patients and controls were well matched. Two endpoints were considered. Breast cancer-specific survival (p = 0.19) and disease-free survival (p = 0.08) times for the vitamin/mineral treated group were shorter, after adjusting for diagnostic variables using a Cox proportional hazards model. The hazard ratios for the vitamin/mineral treated group versus the control group were estimated at 1.75 (95% CI = 0.83–2.69) for disease-specific survival and 1.55 (95% CI = 0.94–2.54) for disease-free survival. Overall survival was similar for the two groups (log-rank test, p = 0.36).

Interpretation. Breast cancer-specific survival and disease-free survival times were not improved for the vitamin/mineral treated group over those for the controls.

breast cancer complementary therapy historical cohort study minerals survival vitamins 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Tagliaferri M, Cohen I, Tripathy D: Complementary and al-ternative medicine in early-stage breast cancer. Semin Oncol 28: 121–134, 2001Google Scholar
  2. 2.
    Morris KT, Johnson N, Homer L, Walts D: A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Amer J Surg 179: 407–411, 2000Google Scholar
  3. 3.
    Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T: Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18: 2515–2521, 2000Google Scholar
  4. 4.
    Jacobson JS, Workman SB, Kronenber F: Research on com-plementary/ alternative medicine for patients with breast can-cer: a review of the biomedical literature. J Clin Oncol 18: 668–683, 2000Google Scholar
  5. 5.
    Sobin LH, Wittekind CH (eds): TNM Classification of Malig-nant Tumours. 5th edn, Wiley, New York, 1997, pp 121–130Google Scholar
  6. 6.
    Elston CW, Willis IO: Pathological prognostic factors in breast cancer: the value of histological grade in breast can-cer – experience from a large study with long-term follow-up. Histopathology 19: 403–410, 1991Google Scholar
  7. 7.
    Kalbfleisch JD, Prentice RL: The Statistical Analysis of Fail-ure Time Data. Wiley, New York, 1980Google Scholar
  8. 8.
    Klein JP, Moeschberger ML: Survival Analysis: Techniques for Censored and Truncated Data. Springer-Verlag, New York, 1997Google Scholar
  9. 9.
    Therneau T, Grambsch P: Modeling Survival Data: Extending the Cox model 2000. Springer-Verlag, New YorkGoogle Scholar
  10. 10.
    Olivotto IA, Coldman AJ, Hislop TG, Trevisan CH, Kula J, Goel V, Sawka C: Compliance with practice guidelines for node-negative breast cancer. J Clinic Oncol 15: 216–222, 1997Google Scholar
  11. 11.
    Wright S, Monro J, Payne M, James N, Reed A: Bristol Cancer Help Centre. Lancet 336: 743–744, 1990Google Scholar
  12. 12.
    Bagenal FS, Easton DF, Harris E et al.: Survival of pa-tients with breast cancer attending Bristol Cancer Help Centre. Lancet 336: 606–610, 1990Google Scholar
  13. 13.
    Hoffer A, Pauling L: Hardin Jones biostatistical analysis of mortality data for a second set of cohorts of cancer patients with a large fraction surviving at the termination of the study and a comparison of survival times of cancer patients receiv-ing large regular doses of vitamin C and other nutrients with similar patients not receiving these doses. J Orthomol Med 8: 157–167, 1993Google Scholar
  14. 14.
    Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirex AJ: Influence of delay on survival in patients with breast cancer: a systematic review. Lancet 353: 1119–1126, 1999Google Scholar
  15. 15.
    Fisher B, Anderson S, Redmond C, Wolmark N, Wickerham DL, Cronin WM: Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. New England J Med 333: 1456–1461, 1995Google Scholar
  16. 16.
    Clark RM, Whelan T, Levine M, Roberts R, Willan A, McCulloch P, Lipa M, Wilkinson RH, Mahoney LJ: Random-ized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. J Natl Cancer Inst 88: 1659–1664, 1996Google Scholar
  17. 17.
    Siegel BS: Love, Medicine and Miracles. Arrow Books, London, 1988Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • M.L. Lesperance
    • 1
  • I.A. Olivotto
    • 2
  • N. Forde
    • 3
  • Y. Zhao
    • 4
  • C. Speers
    • 5
  • H. Foster
    • 1
  • M. Tsao
    • 1
  • N. MacPherson
    • 2
  • A. Hoffer
    • 6
  1. 1.University of VictoriaCanada
  2. 2.British Columbia Cancer Agency-Vancouver Island CentreVictoriaCanada
  3. 3.ICESTorontoCanada
  4. 4.University of WaterlooWaterlooCanada
  5. 5.Breast Cancer Outcomes UnitBritish Columbia Cancer AgencyVancouverCanada
  6. 6.Canada

Personalised recommendations